Table 4.
Characteristics of patients with HCC development.
Patients No | Sex/age | HCC occurrence | Baseline LS | LS at 48 week | LS at 96 week | LS at 144 week |
---|---|---|---|---|---|---|
1 | M/59 | 96 weeks | 38.0 | 28.4 (− 25.3%) | 26.7 (−29.7%) | |
2 | F/76 | 96 weeks | 32.1 | 25.1 (− 21.8%) | 35.0 (+ 0.09%) | |
3 | M/69 | 96 weeks | 45.0 | 39.0 (−13.3%) | 13.4 (−70.2%) | |
4 | F/75 | 144 weeks | 25.7 | 20.0 (−22.2%) | 14.5 (−43.6%) | 19.8 |
5 | M/63 | 144 weeks | 17.6 | 12.0 (−31.8%) | 9.7 (−44.9%) | 10.5 |
HCC, hepatocellular carcinoma; LS, liver stiffness.